Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiviral drug |
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States |
| gptkbp:ATCCode |
gptkb:J05AP55
|
| gptkbp:brand |
gptkb:Vosevi
|
| gptkbp:CASNumber |
1535212-07-7
|
| gptkbp:combines |
gptkb:sofosbuvir
velpatasvir |
| gptkbp:developedBy |
gptkb:Gilead_Sciences
|
| gptkbp:eliminationHalfLife |
33 hours
|
| gptkbp:hasMolecularFormula |
C40H52F4N6O9S
|
| https://www.w3.org/2000/01/rdf-schema#label |
voxilaprevir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
NS3/4A protease inhibitor
|
| gptkbp:pregnancyCategory |
B1 (Australia)
N (US) |
| gptkbp:proteinBinding |
>99.5%
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3989989
71545361 DB13879 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue headache |
| gptkbp:UNII |
6Y1K2V4S2F
|
| gptkbp:usedFor |
treatment of hepatitis C
|
| gptkbp:bfsParent |
gptkb:HCV_NS3/4A_protease
gptkb:NS3/4A_serine_protease gptkb:velpatasvir_and_voxilaprevir |
| gptkbp:bfsLayer |
7
|